Showing results (281-290 of 463) with videos related to
Sort By:
Pageof 47
Pharmacogenomics|May 7, 2014
Pharmacogenomics: from cell to clinic (Part 1)Gérard Siest, Rui Medeiros, Bohuslav Melichar, et al.Thrombosis and Haemostasis|June 24, 2004
The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumonLoes E Visser, Ron H N van Schaik, Martin van Vliet, et al.Clinical Pharmacology and Therapeutics|June 18, 2005
Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulantsLoes E Visser, Ron H N van Schaik, Martin van Vliet, et al.Journal of Intensive Care Medicine|May 3, 2018
Early Prediction of Intensive Care Unit-Acquired Weakness: A Multicenter External Validation StudyEsther Witteveen, Luuk Wieske, Juultje Sommers, et al.Pharmacogenomics|April 21, 2009
Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderlyMonique J Bijl, Hendrika J Luijendijk, Julia F van den Berg, et al.Pharmacogenetics and Genomics|June 15, 2007
The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9Loes E Visser, Ron H N van Schaik, Alexander H Jan Danser, et al.Journal of the Peripheral Nervous System : JPNS|January 24, 2019
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra studyOrell Mielke, Vera Bril, David R Cornblath, et al.The Pharmacogenomics Journal|April 24, 2026
The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamineDaniël T Coerts, Sanne Y Smith-Apeldoorn, Jérôme C Oude Nijhuis, et al.Trials|February 20, 2021
Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC)S R M Bus, L Zambreanu, A Abbas, et al.Clinical Pharmacology and Therapeutics|December 14, 2004
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genesDennis A Hesselink, Teun van Gelder, Ron H N van Schaik, et al.Pageof 47